CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. It offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure (HF) with reduced ejection fraction or systolic HF. The company sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, rest of Europe, and internationally. CVRx, Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Revenue of CVRx, Inc. (CVRX)
Revenue in 2023 (TTM): $39.3 M
According to CVRx, Inc.'s latest financial reports the company's current revenue (TTM) is $39.3 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of CVRx, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $39.3 M | $33.04 M | $-38,731,000 | $-41,052,000 | $-41,199,000 |
| 2022 | $22.47 M | $17.47 M | $-40,742,000 | $-41,319,000 | $-41,428,000 |
| 2021 | $13.04 M | $9.4 M | $-40,600,000 | $-42,987,000 | $-43,078,000 |
| 2020 | $6.05 M | $4.61 M | $-11,479,000 | $-14,024,000 | $-14,109,000 |
| 2019 | $6.26 M | $4.57 M | $-12,784,000 | $-14,560,000 | $-14,633,000 |